Baseline Pneumococcal IgG Levels and Response to 23-Valent Pneumococcal Polysaccharide Vaccine among Adults from Beijing, China
Author:
Zhou Shanshan1, Lv Min1, Bai Shuang1, Chen Weixin1, Zhao Wei1ORCID, Wang Jian1, Zhang Ao1, Li Jing1, Xie Hui1, Gao Yanqing2, Li Dongmei2, Wu Jiang1
Affiliation:
1. Beijing Center for Disease Prevention and Control, No. 16, Hepingli Middle Street, Dongcheng District, Beijing 100013, China 2. Daxing District Center for Disease Control and Prevention of Beijing, Beijing 102600, China
Abstract
Purpose: To investigate the baseline levels of serotype-specific IgG antibodies to Streptococcus pneumoniae (S. pneumoniae) and assess their impact on the assessment of vaccine immunogenicity. Methods: We used a subset of serum samples from a randomized controlled trial. The blood of 584 healthy participants was collected on day 0 before and day 28 after the 23-valent pneumococcal polysaccharide vaccine (PPSV23) vaccination. Serotype-specific IgG against PPSV23-covered serotypes were measured by the World Health Organization (WHO) reference enzyme-linked immunosorbent assay (ELISA). Vaccine immunogenicity was compared using conversion rates (proportion of participants with IgG levels following immunization that are 2-fold greater than the baseline) and geometric mean fold rises (GMFRs) between the two groups, which were grouped according to pre-vaccination (baseline) IgG antibody levels. Results: Our data showed that over half of individuals have baseline IgG levels for 15 out of 23 serotypes above 1.3 µg/mL, and geometric mean concentrations (GMCs) were generally higher in the elderly group and the female group; significant differences were found in 15 serotypes for vaccine immunogenicity based on the seroconversion rate or GMFRs between individuals with baseline IgG ≥ 1.3 µg/mL and individuals with baseline IgG < 1.3 µg/mL. The seroconversion rate decreased with the increase of baseline IgG levels according to a linear regression model. Conclusions: The assessment of vaccine immunogenicity could be impacted by the fact that many adults had high baseline antibody levels. This study is registered in the Chinese Clinical Trial Registry, number NCT05298800.
Funder
Beijing Natural Science Foundation–Haidian Original Innovation Joint Fund Project construction of high-level public health technical personnel from Beijing Municipal Health Commission
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference40 articles.
1. Waz, N.T., Oliveira, S., Girardello, R., Lincopan, N., Barazzone, G., Parisotto, T., Hakansson, A.P., Converso, T.R., and Darrieux, M. (2022). Influence of the Polysaccharide Capsule on the Bactericidal Activity of Indolicidin on Streptococcus pneumoniae. Front. Microbiol., 13. 2. Pneumococcal Capsules and Their Types: Past, Present, and Future;Geno;Clin. Microbiol. Rev.,2015 3. Serotype Distribution and Disease Severity in Adults Hospitalized with Streptococcus pneumoniae Infection, Bristol and Bath, UK, 2006–2022;Hyams;Emerg. Infect. Dis.,2023 4. (2008). Meeting of the Immunization Strategic Advisory Group of Experts, November 2007—Conclusions and recommendations. Wkly. Epidemiol. Rec., 83, 1–15. 5. Prevention of pneumococcal diseases: The challenge remains;Dhoubhadel;Lancet Glob. Health.,2022
|
|